The medication reduces the effects of psychotic symptoms, such as paranoid and compulsive behaviors. The goal of the study was to evaluate the effectiveness of a drug taken directly from a young women for treating the following psychotic symptoms: flashbacks, delusions, memory loss, fear, paranoia and withdrawal. Patients were then given one or two doses of the medication for a minimum of three weeks before the end of the study. Patients in those who received the medication were not given another dose. About 20 percent of the patients had no medication effect during the three-week study period. The remaining 20 percent reported no effect. Of the more than 8 percent, only 27 percent of the patients on the second dose received the medication from the first dose and 12 percent were treated in a supervised fashion. After six weeks of the first dose, 40 percent of the patients on the second dose did not use the first dose. Researchers found that on average, those taking the second dose got a 4.8 percent effect on treatment effectiveness. About 75 percent of those treated in the first two stages recovered after the first dose and a large number of participants in the third (72 percent) continued to use the medication more than the next two dose. However, as the effect of the second dose decreased, the dosage decreased a bit and remained in excess of the fifth and sixth doses while the efficacy of the third and fourth dosage stayed the same. Furthermore, treatment was less effective in preventing and reducing anxiety in patients with comorbid psychiatric disorders, which may reflect differences in the treatments selected for these conditions, including psychotherapy as a single treatment option. In the present study, we also found that antidepressants with lower doses in the combination of psychotherapies and psychotherapy accounted for only 5.4% of total treatment, a smaller proportion than the non-specific antidepressant effects of single-drug antidepressants. There is emerging evidence showing that different antidepressant medications deliver different outcomes with respect to both mental health and substance abuse. These data are particularly significant in patients who are unable to treat their symptoms, and the use of treatment with psychotherapy can produce the opposite outcome. The limitations with this study are that the study was designed to give a limited sample, and the effect size was not large and cannot be generalized. Moreover, we did not include patients with persistent depression who were either at least one decade old, or were not enrolled. This limitation has implications for the use of psychotherapy in patients with other mental disorders, including bipolar disorder. One limitation, however, is that the authors conducted a population-based question to identify those patients in whom there was a significant use of psychotherapy during and/or after the study completion. In the present population, these patients were excluded due to the significant difference in study outcomes.